Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Benjamin Levy is a thoracic medical oncologist and the clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, as well as an assistant professor of oncology for Johns Hopkins University School of Medicine. Dr. Levy is board certified in medical oncology and hematology by the American Board of Internal Medicine. He practices out of the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital. 

2020 CBPD LEVY - CASE 1 - Timing and Treatment for 48 YO Male with EGFR NSCLC High PDL1
2020 Case Based Panel Discussions, Dr. Ben LEVY - CASE 1 - Timing and Treatment for 48 year old male with high PDL1, lung mass and disseminated cancer across both lungs, and no real comorbidities
Author
Benjamin Levy, MD, Faculty
Image
For this series of Case Based Panel Discussions,  Dr. Benjamin Levy is joined by Dr. Stephen Liu and Dr. Julie Brahmer to discuss treatment for specific cases in Lung Cancer.

Dr. Levy is Associate Professor of Oncology and Clinical Director of Medical Oncology and Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, and sits on the board of GRACE. Dr. Liu is Associate Professor of Medicine and Director of Thoracic Oncology and Director of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. Dr. Julie Brahmer is Director of the Thoracic Oncology Program and Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

 

For this series, the doctors review cases related to EGFR positive NSCLC.

In this video, the case discussion surrounds timing and treatment for a 48 year old male with high PDL1, lung mass and disseminated cancer across both lungs, and no real comorbidities.

 

We thank AstraZeneca Merck Genentech Takeda and Lilly for their support!

 

To join the conversation, visit https://cancergrace.org/forum.

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora